Diet Report - Pharmaceuticals - Hantavirus by Elara Capital
Hantavirus
Hantavirus infections remain rare globally, with no specific USFDA -approved vaccines or antiviral treatments available. They are rodent -borne RNA viruses that infect humans primarily through inhalation of aerosolized particles from rodent urine, droppings, or saliva, and only rarely spread from person to person (notably the Andes strain). T hough individual hantavirus infections can be severe and fatal , outbreaks tend to be localized and self -limiting, not reaching pandemic scale . That way it is different fr om Covid -19 virus that spread very fast and became a pandemic, though mortality rate was extremely low.
Two major clinical syndromes: Hantavirus Pulmonary Syndrome (HPS) in America, which leads to severe respiratory failure, and Hemorrhagic Fever with Renal Syndrome (HFRS) in Europe and Asia, which affects the kidneys and blood vessels. Symptoms begin as flu -like illness and can rapidly progress to life -threatening complications, with mortality rates reaching 40 – 50% in HPS and up to 15% in severere HFRS strains. There are no vaccines or treatment available for Hantavirus diseases.
Historical outbreaks: The first recognized outbreak of HPS occurred in 1993 in the Four Corners region of the US (Arizona, New Mexico, Colorado & Utah) and was caused by the Sin Nombre virus. There were 53 cases during that outbreak, with 32 deaths, reflecting a high fatality rate. During the Korean War (1951 – 1954), an epidemic of HFRS occurred among United Nations troops near the Hantan River; app roximately 3,200 soldiers were infected, and mortality was initially more than 10% before supportive care impro ved, resulting in an estimated 160 – 320 deaths during that period. In recent decades, China has reported large numbers of HFRS cases; between 2004 and 2019, there were an estimated 210,000 HFRS cases and around 1,855 deaths. In the United States between 199 3 and 2022, a total of 864 hantavirus disease cases were reported, with approximately 302 deaths.
Current situation: A recent 2026 cluster aboard the cruise ship MV Hondius linked to the Andes strain has resulted in a small number of cases and three deaths, drawing attention to the disease but remaining limited in spread.
Little chance of pandemic spread: Hantavirus has a low rate of person -to-person spread compared with respiratory viruses like SARS -CoV -2, the cause of COVID -19. This low transmissibility means that even though individual hantavirus infections can be severe, outbreaks tend to be localized a nd self -limiting, not reaching pandemic scale. COVID -19, in contrast, spreads efficiently between people through respiratory droplets and aerosols, enabling rapid and widespread transmission globally.
India status: As of now, there are no widely reported or officially confirmed deaths from hantavirus in India linked to the current 2026 global outbreak.
Please refer disclaimer at Report
SEBI Registration number is INH000000933
